Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin

Free Radical Biology and Medicine

Volumn 49, Issue 11, 2010, Pages 1710-1721

  Huang, Jiung Pang ^a   Huang, Shiang Suo ^b   Deng, Jen Ying ^a   Chang, Chih Chun ^a   Day, Yuan Ji ^c   Hung, Li Man ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Cardiovascular disease; Diabetes; Free radicals; I R injury; INOS; Insulin; Nitrotyrosine; Resveratrol

Indexed keywords

3 NITROTYROSINE; GLUCOSE TRANSPORTER 4; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INSULIN ZINC SUSPENSION; PROTEIN KINASE B; RESVERATROL; SUPEROXIDE;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLE; DRUG POTENTIATION; ENZYME INHIBITION; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMODYNAMICS; HYPERGLYCEMIA; MALE; MORTALITY; NITROSATIVE STRESS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; SYSTOLE;

ACUTE DISEASE; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DRUG ANTAGONISM; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; HEART FAILURE; HEMODYNAMICS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, SPRAGUE-DAWLEY; STILBENES; STREPTOZOCIN; VASODILATOR AGENTS;

ANIMALIA; RATTUS; RICE STRIPE VIRUS;

EID: 78049356035     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.08.032     Document Type: Article

References (41)

1. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
2. Geiss L.S., Herman W.H., Smith P.J. Diabetes in America. NIH Publication No. 95-1468 1995, 233-257. National Institutes of Health, Bethesda, MD.
3. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
4. Aguilar D., Solomon S.D., Kober L., Rouleau J.L., Skali H., McMurray J.J., Francis G.S., Henis M., O'Connor C.M., Diaz R., Belenkov Y.N., Varshavsky S., Leimberger J.D., Velazquez E.J., Califf R.M., Pfeffer M.A. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Circulation 2004, 110:1572-1578.
5. Stevens R.J., Coleman R.L., Adler A.I., Stratton I.M., Matthews D.R., Holman R.R. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diab. Care 2004, 27:201-207.
6. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease: the Framingham Study. JAMA 1979, 241:2035-2038.
7. Abbott R.D., Donahue R.P., Kannel W.B., Wilson P.W. The impact of diabetes on survival following myocardial infarction in men vs. women: the Framingham Study. JAMA 1988, 260:3456-3460.
8. Regan T.J., Lyons M.M., Ahmed S.S., Levinson G.E., Oldewurtel H.A., Ahmad M.R., Haider B. Evidence of cardiomyopathy in familial diabetes mellitus. J. Clin. Invest. 1977, 60:884-899.
9. Takaoka M.J. Of the phenolic substances of white hellebore (Veratrum grandiflorum Loes. fil.). J. Faculty Sci. Hokkaido Imperial University 1940, 3:1-16.
10. Spector K.S. Diabetic cardiomyopathy. Clin. Cardiol. 1998, 21:885-887.
11. Nonomura S., Kanagawa H., Makimoto A. Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-jo-kon (Polygonum capsidatum-SIEB et ZUCC). Yakugaku Zasshi 1963, 83:988-990.
12. Mahgoub M.A., Abd-Elfattah A.S. Diabetes mellitus and cardiac function. Mol. Cell. Biochem. 1998, 180:59-64.
13. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J. 2003, 17:1975-1985.
14. Hung L.M., Chen J.K., Huang S.S., Lee R.S., Su M.J. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc. Res. 2000, 47:549-555.
15. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H.S., Farnsworth N.R., Kinghorn D.A., Mehta R.G., Moon R.C., Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a nature product derived from grapes. Science 1997, 275:218-220.
16. Frankel E.N., Waterhouse A.L., Kinsella J.E. Inhibition of human LDL oxidation by resveratrol. Lancet 1993, 341:1103-1104.
17. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discovery 2006, 5:493-506.
18. Su H.C., Hung L.M., Chen J.K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E1339-E1346.
19. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
20. Pacholec M., Bleasdale J.E., Chrunyk B., Cunningham D., Flynn D., Garofalo R.S., Griffith D., Griffor M., Loulakis P., Pabst B., Qiu X., Stockman B., Thanabal V., Varghese A., Ward J., Withka J., Ahn K. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H833-H843.
21. Zhang H., Zhang J., Ungvari Z., Zhang C. Resveratrol improves endothelial function: role of TNFα and vascular oxidative stress. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1164-1171.
22. Thirunavukkarasu M., Penumathsa S.V., Koneru S., Juhasz B., Zhan L., Otani H., Bagchi D., Das D.K., Maulik N. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic. Biol. Med. 2007, 43:720-729.
23. Zang M., Xu S., Maitland-Toolan K.A., Zuccollo A., Hou X., Jiang B., Wierzbicki M., Verbeuren T.J., Cohen R.A. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006, 55:2180-2191.
24. DeSouza C., Fonseca V. Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nat. Rev. Drug Discovery 2009, 8:361-367.
25. Gand O.P., Rossi A.A., Like A.A. Studies on streptozotocin diabetes. Diabetes 1976, 25:595-603.
26. Hung L.M., Su M.J., Chen J.K. Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radic. Biol. Med. 2004, 36:774-781.
27. Walker M.J., Curtis M.J., Hearse D.J., Campbell R.W., Janse M.J., Yellon D.M., Cobbe S.M., Coker S.J., Harness J.B., Harron D.W.G., Higgins A.J., Julian D.G., Lab M.J., Manning A.S., Northover B.J., Parratt J.R., Riemersma R.A., Riva E., Russell D.C., Sheridan D.J., Winslow E., Woodward B. The Lambeth Convention: guidelines for the study of arrhythmias in ischemia, infarction and reperfusion. Cardiovasc. Res. 1988, 22:447-455.
28. Pacher P., Nagayama T., Mukhopadhyay P., Bátkai S., Kass D.A. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat. Protoc. 2008, 3:1422-1434.
29. Deng J.Y., Huang J.P., Lu L.S., Hung L.M. Impairment of cardiac insulin signaling and myocardial contractile performance in high-cholesterol/fructose-fed rats. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H978-H987.
30. Hung L.M., Su M.J., Chu W.K., Chiao C.W., Chan W.F., Chen J.K. The protective effect of resveratrol on ischemia-reperfusion injuries of the rat hearts is correlated with antioxidant efficacy. Br. J. Pharmacol. 2002, 135:1627-1633.
31. Wohaieb S.A., Godin D.V. Alterations in free radical tissue-defense mechanisms in streptozotocin-induced diabetes in rat: effects of insulin treatment. Diabetes 1987, 36:1014-1018.
32. Litwin S.E., Raya T.E., Anderson P.G., Daugherty S., Goldman S. Abnormal cardiac function in the streptozotocin-diabetic rat: changes in active and passive properties of the left ventricle. J. Clin. Invest. 1990, 86:481-488.
33. Huang J.P., Huang S.S., Deng J.Y., Hung L.M. Impairment of insulin-stimulated Akt/GLUT4 signaling is associated with cardiac contractile dysfunction and aggravates I/R injury in STZ-diabetic rats. J. Biomed. Sci. 2009, 16:77.
34. Klein L., Gheorghiade M. Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update. Am. J. Med. 2004, 116(Suppl. 5A):47S-63S.
35. Murcia A.M., Hennekens C.H., Lamas G.A., Jimenez-Navarro M., Rouleau J.L., Flaker G.C., Goldman S., Skali H., Braunwald E., Pfeffer M.A. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch. Intern. Med. 2004, 164:2273-2279.
36. Poornima I.G., Parikh P., Shannon R.P. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ. Res. 2006, 98:596-605.
37. Haidara M.A., Yassin H.Z., Rateb M., Ammar H., Zorkani M.A. Role of oxidative stress in development of cardiovascular complications in diabetes mellitus. Curr. Vasc. Pharmacol. 2006, 4:215-227.
38. Kim J.A., Montagnani M., Koh K.K., Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888-1904.
39. Ceriello A., Quagliaro L., D'Amico M., Di Filippo C., Marfella R., Nappo F., Berrino L., Rossi F., Giugliano D. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes 2002, 51:1076-1082.
40. Hoeldtke R.D. Nitrosative stress in early type 1 diabetes. Clin. Auton. Res. 2003, 13:406-421.
41. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., Raskin P., Zinman B. Intensive diabetes treatment and cardiovascular disease in type 1 diabetes mellitus. N Engl J. Med. 2005, 353:2643-2653.